USV enters Germany by snapping up Juta
Executive Summary
Privately-owned Indian company USV is entering “the highly competitive German drug market” by acquiring local generics player Juta Pharma for an undisclosed fee. The German firm – which has “more than 50 marketing authorisations for generic drugs” – was part of Watson’s Arrow Group until a management buy-out in 2013.
You may also be interested in...
India's USV Reveals Investment Plans
Indian firm USV plans to spend $56.4m on a new drug formulations unit in Vadodara and $11.3m to upgrade its existing API unit near Mumbai as it eyes expanded capacity and additional sales in Europe.
USV’s Juta Gets An EU Pegfilgrastim Nod
Juta Pharma has received a positive opinion from the European Medicines Agency’s CHMP recommending granting a pan-European marketing authorization for its biosimilar pegfilgrastim, Grasustek.
Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: